Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

oche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the Company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements related to the further development and potential safety, efficacy, commercialization and other characteristics of tanespimycin, Kosan's development plans with respect to tanespimycin, including but not limited to Kosan's plans and timing for the initiation of the TIME-1 trial and TIME-2 as a potential registration trial, and the FDA's later review of the results of the TIME-1 clinical trial. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, risks related to the development of tanespimycin, including the risk that studies and ongoing trials may not demonstrate safety and efficacy sufficient to initiate additional clinical trials, continue clinical development on the timing currently anticipated or at all, obtain the requisite regulatory approvals or result in a marketable product; risks related to regulatory requirements and other risks detailed from time to time in the Kosan's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward- looking statements.

'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...   Direct to implant, or "one step," ... option for many women with BRCA (BReast CAncer) ... cancer risk, or with breast cancer. Traditionally, post-mastectomy ... second surgery to insert permanent implants, but immediate ... mastectomy can be a medically and cosmetically effective ...
(Date:5/23/2013)...  Net Medical Xpress Solutions, Inc., (OTC QB: NMXS), ... company has signed a letter of intent to acquire ... Huntsville, AL . MedTel Solutions is a ... recruitment of telemedicine physicians. Consideration for the acquisition will ... is expected by June 30, 2013. Dick ...
(Date:5/23/2013)... 23, 2013 Israel Brain Technologies (IBT) ... Israel,s 1 st International Brain ... -15 th in Tel Aviv , ... in the world by the Wall Street Journal ... Israel 2013 will showcase the latest breakthroughs in neuroscience and ...
Breaking Medicine Technology:Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... , EMERYVILLE, Calif. , July 29 Bionovo, Inc. ... from the European Medicines Agency (EMA) in order to advance Menerba, the ... in Europe . The guidance defines the clinical and regulatory pathway ... , , ...
... joined 19 pro-life groups in a letter sent to Food and Drug Administration (FDA) Commissioner ... can cause abortions but is misleadingly labeled as an "emergency contraceptive," not be approved. ... Tom McClusky , FRC ... , , ...
Cached Medicine Technology:Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe 2Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe 3FRC Action and Pro-Life Coalition Urge the FDA to Reject New Abortion-Causing Drug 2
(Date:5/23/2013)... 2013 Magnatag’s new magnetic 365-Day attendance ... reduces vacation conflicts. A Manufacturing Manager from Augusta GA ... now employees and managers can check the board for ... is important to us and the board makes the ... seem harsh but it has made a difference.” ...
(Date:5/23/2013)... Magic often happens unexpectedly. "Howie Goes to ... twin five-year olds, Howie and his sister Heather, at ... in point. May 23, 2013 marks the debut of ... with the start of the Resort's "WeTime/MeTime” program, ... amenities and, most precious of all, opportunities for children and ...
(Date:5/23/2013)... Littleton, CO (PRWEB) May 23, 2013 ... environment, Special Operations Forces and law enforcement need an ... Night Vision Security Enhancer, Night VISER , is ... illuminator and motion sensing system to increase border and ... for Night VISER have more than tripled over the ...
(Date:5/23/2013)... DEER, Alberta (PRWEB) May 24, 2013 On ... in every nine women will hear in her lifetime: she ... My Knees: My Journey After a Breast Cancer Diagnosis ” ... days that followed. , Rideout drew from her daily journals ... like going through surgery, chemotherapy and radiation treatments to deal ...
(Date:5/23/2013)... Voyance, the ASC industry’s leading ... and ASCA, the industry’s national membership association, are ... Program. Voyance will leverage their decade ... experience to support ASCA’s goal to provide the ... , “Voyance is both excited and proud to ...
Breaking Medicine News(10 mins):Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 2Health News:New Children's Comic Book, "Howie Goes to Maui," Launches May 23, 2013 On Four Seasons Resort Maui's Web Site 3Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Kimberley Rideout Shares Her Triumphant Cancer Survival Story 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3
... , WEDNESDAY, Jan. 11 (HealthDay News) -- The first ... cancer has been identified by scientists. Men who inherit the ... increased risk of developing prostate cancer, according to the study in ... Medicine . The HOXB13 gene plays an important role in ...
... 11 (HealthDay News) -- Researchers have identified a protein in ... exercise in mice. "There has been a feeling ... the body," said the study,s senior author, Bruce Spiegelman, a ... professor of cell biology at Harvard Medical School, in a ...
... Researchers have discovered that a subtype of leukemia characterized ... pathways distinctly different from a seemingly similar leukemia associated ... St. Jude Children,s Research Hospital Washington University Pediatric ... for treating patients with this more aggressive cancer. ...
... stent in a key artery in the neck is safer ... of carotid artery disease, according to a new study published ... A team of researchers led by Dr. Jon ... Wisconsin School of Medicine and Public Health, found the clinical ...
... By Madonna Behen HealthDay Reporter , WEDNESDAY, Jan. ... killer in the world, and only about 15 percent of ... treatable. But two preliminary studies that are scheduled to ... scientists are moving closer to developing new screening tests that ...
... condescendingly, excluded from a meeting, or ignored by a supervisor. ... depending on whether your co-worker is a man or a ... towards colleagues feel negative emotions especially when the incivility ... by Kathi Miner from Texas A&M University and Angela Eischeid ...
Cached Medicine News:Health News:Scientists Identify Inherited Prostate Cancer Gene 2Health News:Mouse Study Give Clues to Why Exercise Is Healthy 2Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 2Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 3Health News:Cancer sequencing project identifies potential approaches to combat aggressive leukemia 4Health News:Stenting for stroke prevention becoming safer in high-risk patients 2Health News:Tests Might Someday Help Spot Early Lung Cancer 2Health News:Tests Might Someday Help Spot Early Lung Cancer 3Health News:'I feel your pain ...' 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: